GILD Gilead Sciences Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: GILD

Price (delayed)

$146.12

Market cap

$181.18B

P/E Ratio

N/A

Dividend/share

$3.22

EPS

-$2.6

Enterprise value

$204.25B

?
Relative Growth: Rel. Growth: 50
Relative Strength: Rel. Strength: 56
Relative Valuation: Rel. Valuation: 12
Relative Profitability: Rel. Profitability: 30

For more than 35 years, Gilead has been a leading innovator in the field of HIV, driving advances in treatment, prevention and cure research. Gilead researchers have developed 13 HIV ...

Highlights
GILD's gross profit is up by 7% YoY and by 2.7% QoQ
GILD's revenue is up by 6% year-on-year and by 2.4% since the previous quarter
GILD's EPS has dropped by 151% year-on-year and by 135% since the previous quarter
The company's net income has shrunk by 151% YoY and by 135% QoQ
Sector: Healthcare
Industry: Drug Manufacturers - General
Website: http://www.gilead.com
Peers: AMGN VRTX ABBV ILMN

Key stats

What are the main financial stats of GILD

GILD stock price

How has the Gilead Sciences stock price performed over time
Intraday
1.87%
1 week
5.61%
1 month
12.16%
1 year
25.81%
YTD
19.05%
QTD
15.66%

Financial performance

How have Gilead Sciences's revenue and profit performed over time
Revenue
$30.46B
Gross profit
$24.24B
Operating income
-$2.5B
Net income
-$3.24B
Gross margin
79.6%
Net margin
-10.6%
The company's net income has shrunk by 151% YoY and by 135% QoQ
Gilead Sciences's net margin has shrunk by 148% YoY and by 134% QoQ
The operating income has dropped by 131% year-on-year and by 124% since the previous quarter
The operating margin has plunged by 129% YoY and by 123% from the previous quarter

Price vs fundamentals

How does GILD's price correlate with its fundamentals

Growth

What is Gilead Sciences's growth rate over time

Valuation

What is Gilead Sciences stock price valuation
GILD P/E details
P/E
N/A
P/B
15.34
P/S
5.96
EV/EBIT
N/A
EV/EBITDA
113.28
EV/Sales
6.71
GILD's EPS has dropped by 151% year-on-year and by 135% since the previous quarter
The stock's price to book (P/B) is 174% more than its 5-year quarterly average of 5.6 and 83% more than its last 4 quarters average of 8.4
Gilead Sciences's equity has decreased by 50% from the previous quarter and by 40% YoY
GILD's price to sales (P/S) is 53% more than its 5-year quarterly average of 3.9 and 15% more than its last 4 quarters average of 5.2
GILD's revenue is up by 6% year-on-year and by 2.4% since the previous quarter

Efficiency

How efficient is Gilead Sciences business performance
GILD's return on assets has dropped by 152% year-on-year and by 136% since the previous quarter
The company's return on equity has shrunk by 150% YoY and by 139% QoQ
Gilead Sciences's ROIC has plunged by 111% YoY and by 108% from the previous quarter
GILD's return on sales has dropped by 111% year-on-year and by 108% since the previous quarter

Dividends

What is GILD's dividend history
Dividend details
DPS
$3.22
Dividend yield
2.2%
Payout ratio
N/A
Recent dividends

Special dividends are included in TTM DPS and yield

Financial health

How did Gilead Sciences financials performed over time
GILD's total assets is 31% higher than its total liabilities
The quick ratio has contracted by 43% from the previous quarter and by 16% YoY
Gilead Sciences's current ratio has decreased by 36% QoQ and by 3.8% YoY
Gilead Sciences's debt is 122% higher than its equity
The company's debt to equity has surged by 136% QoQ and by 75% YoY
Gilead Sciences's equity has decreased by 50% from the previous quarter and by 40% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.